Letter
Lipid lowering drugs in diabetes: Lipid lowering has ophthalmic benefits
Cite this as:
BMJ
2006;332:1272.3
- Clinical trials (epidemiology)
- Diabetes
- Endocrinology
- Epidemiologic studies
- Epidemiology
- Metabolic disorders
- Ophthalmology
More topics 
Fewer topics
- Hiten G Sheth, specialist registrar (drhitensheth@yahoo.co.uk),
- Sher Aslam, senior house officer,
- Nigel Davies, consultant
- Department of Ophthalmology, Chelsea and Westminster Hospital, London SW10 9NH
- Department of Ophthalmology, Chelsea and Westminster Hospital, London SW10 9NH
EDITOR—Lipid lowering treatment in diabetes has ophthalmic benefits.1 Diabetic maculopathy is a common cause of loss of sight in diabetic patients and is characterised by retinal oedema and lipid exudates. The use of atorvastatin in diabetic maculopathy has recently been shown in a randomised controlled trial to decrease visible lipid exudates and …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
The decline in the breast cancer incidence is 1.2% and it is not significant.
Published 10 February 2012
'twas ever thus
Published 10 February 2012
The value of historic human remains
Published 10 February 2012
In Praise of British Literature
Published 10 February 2012
Is real shared decision making possible?
Published 10 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (7 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (7 responses)
Published 1 Feb 2012
Search for evidence goes on (5 responses)
Published 17 Jan 2012